<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04294147</url>
  </required_header>
  <id_info>
    <org_study_id>17590</org_study_id>
    <secondary_id>I5Q-MC-CGBC</secondary_id>
    <nct_id>NCT04294147</nct_id>
  </id_info>
  <brief_title>A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist</brief_title>
  <official_title>A Phase 4 Single-Blind Study of Gastrointestinal Transit Time in Adult Patients With Migraine Before and After Initiation of a mAb CGRP Antagonist</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to measure the gastrointestinal emptying time using the wireless&#xD;
      motility capsule (WMC) technology (FDA approved SmartPill™) in adult participants with&#xD;
      migraine who are taking a monoclonal antibody (mAb) calcitonin gene-related peptide (CGRP)&#xD;
      antagonist called galcanezumab or erenumab.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 6, 2020</start_date>
  <completion_date type="Actual">March 5, 2021</completion_date>
  <primary_completion_date type="Actual">March 5, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from Baseline in Colonic Transit Time (CTT), in Hours</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <description>Change from Baseline in CTT, in Hours</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Whole Gut Transit Time (WGTT), in Hours</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <description>Change from Baseline in WGTT, in Hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Gastric Emptying Time (GET), in Hours</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <description>Change from Baseline in GET, in Hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Small Bowel Transit Time (SBTT), in Hours</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <description>Change from Baseline in SBTT, in Hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Combined Small and Large Bowel Transit Time (SLBTT), in Hours</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <description>Change from Baseline in Combined SLBTT, in Hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Motility Index</measure>
    <time_frame>Baseline, Week 2</time_frame>
    <description>Motility index (MI) is a calculated outcome, based on the formula: In (Number of contractions x Σpressure amplitudes +1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from Baseline in Gastrointestinal (GI) Symptom Rating Scale (GSRS)</measure>
    <time_frame>Baseline, Week 4</time_frame>
    <description>Change from Baseline in GSRS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">65</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Galcanezumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Galcanezumab administered subcutaneously (SC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Erenumab</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Erenumab administered SC</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Galcanezumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Galcanezumab</arm_group_label>
    <other_name>LY2951742</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erenumab</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Erenumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Have a diagnosis of migraine, with or without aura, as determined by the study&#xD;
             investigator and in consideration of International Headache Society International&#xD;
             Classification of Headache Disorders - 3rd edition guidelines (ICHD-3 2018)&#xD;
&#xD;
          -  Have a frequency of less than 15 monthly headache days of which up to 14 can be&#xD;
             migraine headache days.&#xD;
&#xD;
          -  Participants can be on no more than 1 other migraine preventive treatment (except for&#xD;
             tricyclic antidepressants and verapamil which are not allowed) as long as: that&#xD;
             participant has had a stable dose of the oral migraine preventive treatment for a&#xD;
             minimum of 2 months or participants have received onabotulinumtoxinA for a minimum of&#xD;
             2 cycles prior to screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participants with a history of gastric bezoars, swallowing disorders, severe dysphagia&#xD;
             to food or pills, suspected or known strictures, fistulas, or physiological/mechanical&#xD;
             GI obstruction&#xD;
&#xD;
          -  History of any abdominal surgery within the past 3 months or GI surgery with the&#xD;
             exception of cholecystectomy, appendectomy, or Nissen fundoplication&#xD;
&#xD;
          -  History of irritable bowel syndrome (IBS), chronic constipation, Crohn's disease,&#xD;
             celiac disease, ulcerative colitis, or diverticulitis&#xD;
&#xD;
          -  Participants with type 1 or type 2 diabetes&#xD;
&#xD;
          -  Participants with cardiac pacemakers or other implanted or portable electromechanical&#xD;
             device&#xD;
&#xD;
          -  Participants with a body mass index of ≥40 kilograms per square meter (kg/m²)&#xD;
&#xD;
          -  Women who are pregnant or nursing&#xD;
&#xD;
          -  Participants currently on mAb CGRP antagonists or have received a mAb CGRP antagonist&#xD;
             within the past 6 months prior to visit 1&#xD;
&#xD;
          -  Participants who have received an oral CGRP antagonist (gepant) in the last 14 days&#xD;
             prior to Visit 1&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Research Institute LLC</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharmacology Research Institute</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMR of Greater New Haven</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>06708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/1yGB1p2tvaIcLCeMb8TZmI</url>
    <description>A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a CGRP Antagonist</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 2, 2020</study_first_submitted>
  <study_first_submitted_qc>March 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2020</study_first_posted>
  <last_update_submitted>March 17, 2021</last_update_submitted>
  <last_update_submitted_qc>March 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>prevention</keyword>
  <keyword>prophylaxis</keyword>
  <keyword>headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erenumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.</ipd_time_frame>
    <ipd_access_criteria>A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

